Gliclazide (CAS 21187-98-4)
See product citations (1)
QUICK LINKS
Gliclazide is a chemical that functions as a hypoglycemic agent in experimental applications. Gliclazide acts by binding to the sulfonylurea receptor on the pancreatic beta cell, leading to the closure of ATP-sensitive potassium channels. This closure results in depolarization of the beta cell membrane, leading to an influx of calcium ions and subsequent insulin release. Gliclazide′s mechanism of action involves stimulating insulin secretion from pancreatic beta cells, thereby reducing blood glucose levels. At the molecular level, it interacts with the sulfonylurea receptor and potassium channels to modulate insulin release. Gliclazide′s function in experimental applications involves its role in studying insulin secretion and glucose regulation mechanisms at the cellular level.
Gliclazide (CAS 21187-98-4) References
- Gliclazide modified release: from once-daily administration to 24-hour blood glucose control. | Harrower, A. 2000. Metabolism. 49: 7-11. PMID: 11078469
- Gliclazide modified release: its place in the therapeutic armamentarium. | Crepaldi, G. and Fioretto, P. 2000. Metabolism. 49: 21-5. PMID: 11078472
- Gliclazide modified release. | McGavin, JK., et al. 2002. Drugs. 62: 1357-64; discussion 1365-6. PMID: 12076188
- Gliclazide: metabolic and vascular effects--a perspective. | Alberti, KG., et al. 1992. Metabolism. 41: 40-5. PMID: 1574015
- Gliclazide and insulin action in human muscle. | Bak, JF. and Pedersen, O. 1991. Diabetes Res Clin Pract. 14 Suppl 2: S61-4. PMID: 1794267
- [The use of gliclazide in individualized sulfonylurea therapy]. | Winkler, G. 2014. Orv Hetil. 155: 541-8. PMID: 24681676
- Is gliclazide a sulfonylurea with difference? A review in 2016. | Singh, AK. and Singh, R. 2016. Expert Rev Clin Pharmacol. 9: 839-51. PMID: 26924475
- Gliclazide-Induced Insulin Autoimmune Syndrome: A Rare Case Report and Review on Literature. | Feng, X., et al. 2016. Endocr Metab Immune Disord Drug Targets. 16: 230-234. PMID: 28017142
- Gliclazide. | Al-Omary, FAM. 2017. Profiles Drug Subst Excip Relat Methodol. 42: 125-192. PMID: 28431776
- Evaluating gliclazide for the treatment of type 2 diabetes mellitus. | Tomlinson, B., et al. 2022. Expert Opin Pharmacother. 23: 1869-1877. PMID: 36300277
- Optimal dosing of gliclazide-A model-based approach. | Mim, SR., et al. 2023. Basic Clin Pharmacol Toxicol. 133: 59-72. PMID: 36999176
- Gliclazide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in diabetes mellitus. | Holmes, B., et al. 1984. Drugs. 27: 301-27. PMID: 6373223
- Gliclazide. An update of its pharmacological properties and therapeutic efficacy in non-insulin-dependent diabetes mellitus. | Palmer, KJ. and Brogden, RN. 1993. Drugs. 46: 92-125. PMID: 7691511
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Gliclazide, 1 g | sc-211561 | 1 g | $61.00 |